Metabolic bone diseases: Treating Paget disease: When matters more than how

Nature Reviews Rheumatology

Volumn 5, Issue 12, 2009, Pages 663-665

  Brown, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE PAIN; BONE REMODELING; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; FRACTURE; HEARING IMPAIRMENT; HUMAN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAGET BONE DISEASE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SHORT SURVEY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEITIS DEFORMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 74949101070     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.230     Document Type: Short Survey

References (10)

1. Langston, A. L. et al. Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J. Bone Miner. Res. doi:10.1359/ JBMR.090709.
2. Siris, E. S. Goals of treatment for Paget's disease of bone. J. Bone Miner. Res. 14 (suppl. 2), 49-52 (1999).
3. Selby, P. L., Davie, M. W. J., Ralston, S. H. & Stone, M. D. Guidelines on the management of Paget's disease of bone. Bone 31, 366-373 (2002).
4. Wermers, R. A., Tiegs, R. D., Atkinson, E. J., Achenbach, S. J. & Melton, L. J. 3rd. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J. Bone Miner. Res. 23, 819-825 (2008).
5. Miller, P. D. et al. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am. J. Med. 106, 513-520 (1999).
6. Reid, i. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898-908 (2005).
7. Josse, R. G. et al. Diagnosis and treatment of Paget's disease of bone. Clin. Invest. Med. 30, e210-e223 (2007).
8. Meunier, P. J. & Vignon, E. Therapeutic strategy in Paget's disease of bone. Bone 17, s489-s491 (1999).
9. Altman, R. D. et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N. Engl. J. Med. 289, 1379-1384 (1973).
10. Fraser, W. D., Stamp, T. C., Creek, R. A., Sawyer, J. P. & Picot, C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad. Med. J. 73, 496-502 (1997).